循环肿瘤细胞在上皮性卵巢癌诊治中的进展

doi:10.12280/gjfckx.20200979

摘要/Abstract

摘要：

卵巢癌发病隐匿,早期病变症状不明显,约70%的患者被发现时已进入中晚期,失去了最佳治疗时机。由肿瘤原发灶脱落进入血液循环的循环肿瘤细胞（circulating tumor cell,CTC）被认为是具有巨大诊断、预后潜能的肿瘤标志物。目前的研究发现CTC检测对上皮性卵巢癌的早期诊断、疗效监测及预后评估等有指导意义,并可能成为比CA-125更好的监测方法。近年来,更多的学者对于上皮性卵巢癌的CTC检测方法和临床应用进行了深入研究。综述几种典型的上皮性卵巢癌CTC捕获和鉴定的方法,CTC在上皮性卵巢癌诊治中的临床意义及其临床应用转化的前景。

关键词: 卵巢肿瘤, 肿瘤细胞,循环, 生物标记,肿瘤, CA-125抗原, 诊断, 治疗, 预后

Abstract:

Ovarian cancer develops insidiously without particular early-stage symptoms. About 70% of the patients are found to have entered advanced stage, and have lost the best treatment opportunity. Circulating tumor cell(CTC) that shed from the primary tumor and enter the blood circulation are considered as tumor markers with great diagnostic and prognostic potential. Current studies have found that CTC detection is instructive for the early diagnosis, treatment efficacy monitoring and prognosis assessment of epithelial ovarian cancer, and may be a better monitoring method than CA-125. In recent years, more and more scholars have conducted in-depth studies on the detection methods and clinical applications of CTC in epithelial ovarian cancer. This paper reviews several typical methods for the capture and identification of CTC in epithelial ovarian cancer, the clinical significance of CTC in the diagnosis and treatment of epithelial ovarian cancer and the prospect of their clinical application and transformation.

Key words: Ovarian neoplasms, Neoplastic cells,circulating, Biomarkers,tumor, CA-125 antigen, Diagnosis, Therapy, Prognosis

秦昭娟, 杜逸, 郑艾. 循环肿瘤细胞在上皮性卵巢癌诊治中的进展[J]. 国际妇产科学杂志, 2021, 48(4): 448-452.

QIN Zhao-juan, DU Yi, ZHENG Ai. Progress of Circulating Tumor Cell in the Diagnosis and Treatment of Epithelial Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 448-452.

参考文献 38

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. doi: 10.3322/caac.21551. doi: 10.3322/caac.21551
[2]	Song HJ, Nam KM, Kim JD, et al. Looking for optimized weights of CA125 and HE4 in early screening system of ovarian cancer for Korean patients[J]. Technol Health Care, 2015, 24(Suppl 1):S163-S170. doi: 10.3233/THC-151065. doi: 10.3233/THC-151065
[3]	Maly V, Maly O, Kolostova K, et al. Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer[J]. In Vivo, 2019, 33(4):1027-1037. doi: 10.21873/invivo.11571. doi: 10.21873/invivo.11571
[4]	Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review[J]. Clin Genet, 2019, 95(6):643-660. doi: 10.1111/cge.13514. doi: 10.1111/cge.13514 pmid: 30671931
[5]	Bailey PC, Martin SS. Insights on CTC Biology and Clinical Impact Emerging from Advances in Capture Technology[J]. Cells, 2019, 8(6):553. doi: 10.3390/cells8060553. doi: 10.3390/cells8060553
[6]	张骞, 李力. 循环肿瘤细胞在卵巢癌预测和预后中的应用价值[J]. 国际妇产科学杂志, 2018, 45(6):609-615. doi: 10.3969/j.issn.1674-1870.2018.06.002. doi: 10.3969/j.issn.1674-1870.2018.06.002
[7]	Chebouti I, Kuhlmann JD, Buderath P, et al. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer[J]. Oncotarget, 2017, 8(15):24303-24313. doi: 10.18632/oncotarget.13286. doi: 10.18632/oncotarget.13286 pmid: 28388557
[8]	Shi JH, Guo WZ, Jin Y, et al. Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence[J]. Cancer Med, 2019, 8(3):1269-1278. doi: 10.1002/cam4.2006. doi: 10.1002/cam4.2006
[9]	Aktas B, Kasimir-Bauer S, Heubner M, et al. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy[J]. Int J Gynecol Cancer, 2011, 21(5):822-830. doi: 10.1097/IGC.0b013e318216cb91. doi: 10.1097/IGC.0b013e318216cb91
[10]	Coelho R, Marcos-Silva L, Ricardo S, et al. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment[J]. Expert Rev Anticancer Ther, 2018, 18(2):177-186. doi: 10.1080/14737140.2018.1418326. doi: 10.1080/14737140.2018.1418326
[11]	Hyun KA, Koo GB, Han H, et al. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer[J]. Oncotarget, 2016, 7(17):24677-24687. doi: 10.18632/oncotarget.8250. doi: 10.18632/oncotarget.8250
[12]	Zhang X, Li H, Yu X, et al. Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker[J]. Cell Physiol Biochem, 2018, 48(5):1983-1994. doi: 10.1159/000492521. doi: 10.1159/000492521
[13]	Yousefi M, Dehghani S, Nosrati R, et al. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles[J]. Cell Oncol(Dordr), 2020, 43(4):515-538. doi: 10.1007/s13402-020-00513-9. doi: 10.1007/s13402-020-00513-9
[14]	Mohan S, Chemi F, Brady G. Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer[J]. Transl Lung Cancer Res, 2017, 6(4):454-472. doi: 10.21037/tlcr.2017.06.04. doi: 10.21037/tlcr.2017.06.04
[15]	郑颖龄, 仝进毅. 循环肿瘤细胞检测在妇科恶性肿瘤中应用的研究进展[J]. 中国实用妇科与产科杂志, 2018, 34(1):123-127. doi: 10.19538/j.fk2018010127. doi: 10.19538/j.fk2018010127
[16]	Yoo CE, Moon HS, Kim YJ, et al. Highly dense,optically inactive silica microbeads for the isolation and identification of circulating tumor cells[J]. Biomaterials, 2016, 75:271-278. doi: 10.1016/j.biomaterials.2015.10.033. doi: 10.1016/j.biomaterials.2015.10.033
[17]	Gasiorowski L, Dyszkiewicz W, Zielinski P. In-vivo isolation of circulating tumor cells in non-small cell lung cancer patients by CellCollector[J]. Neoplasma, 2017, 64(6):938-944. doi: 10.4149/neo_2017_618. doi: 10.4149/neo_2017_618 pmid: 28895421
[18]	陈志强, 米贤军, 陈昂, 等. 外周血循环肿瘤细胞检测在筛查卵巢上皮性癌中的应用[J]. 中山大学学报(医学科学版), 2018, 39(6):891-896. doi: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2018.0121. doi: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2018.0121
[19]	Tsai SC, Hung LY, Lee GB. An integrated microfluidic system for the isolation and detection of ovarian circulating tumor cells using cell selection and enrichment methods[J]. Biomicrofluidics, 2017, 11(3):034122. doi: 10.1063/1.4991476. doi: 10.1063/1.4991476
[20]	Tang M, Wen CY, Wu LL, et al. A chip assisted immunomagnetic separation system for the efficient capture and in situ identification of circulating tumor cells[J]. Lab Chip, 2016, 16(7):1214-1223. doi: 10.1039/c5lc01555c. doi: 10.1039/c5lc01555c pmid: 26928405
[21]	Obermayr E, Maritschnegg E, Agreiter C, et al. Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells[J]. Oncotarget, 2018, 9(1):812-823. doi: 10.18632/oncotarget.22549. doi: 10.18632/oncotarget.22549 pmid: 29416657
[22]	PramaniK A, Jones S, Gao Y, et al. Multifunctional hybrid graphene oxide for circulating tumor cell isolation and analysis[J]. Adv Drug Deliv Rev, 2018, 125:21-35. doi: 10.1016/j.addr.2018.01.004. doi: 10.1016/j.addr.2018.01.004
[23]	Han SI, Han KH. Electrical Detection Method for Circulating Tumor Cells Using Graphene Nanoplates[J]. Anal Chem, 2015, 87(20):10585-10592. doi: 10.1021/acs.analchem.5b03147. doi: 10.1021/acs.analchem.5b03147
[24]	Wu S, Liu S, Liu Z, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers[J]. PLoS One, 2015, 10(4):e0123976. doi: 10.1371/journal.pone.0123976. doi: 10.1371/journal.pone.0123976
[25]	Suh DH, Kim M, Choi JY, et al. Circulating tumor cells in the differential diagnosis of adnexal masses[J]. Oncotarget, 2017, 8(44):77195-77206. doi: 10.18632/oncotarget.20428. doi: 10.18632/oncotarget.20428
[26]	Kolostova K, Matkowski R, Jędryka M, et al. The added value of circulating tumor cells examination in ovarian cancer staging[J]. Am J Cancer Res, 2015, 5（11）：3363-3375. [2020-08-30] https://pubmed.ncbi.nlm.nih.gov/26807317/. pmid: 26807317
[27]	Romero-Laorden N, Olmos D, Fehm T, et al. Circulating and disseminated tumor cells in ovarian cancer: a systematic review[J]. Gynecol Oncol, 2014, 133(3):632-639. doi: 10.1016/j.ygyno.2014.03.016. doi: 10.1016/j.ygyno.2014.03.016 pmid: 24657303
[28]	Martini V, Timme-Bronsert S, Fichtner-Feigl S, et al. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives[J]. Cancers(Basel), 2019, 11(11):1659. doi: 10.3390/cancers11111659. doi: 10.3390/cancers11111659
[29]	Giannopoulou L, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA[J]. Clin Chem Lab Med, 2018, 56(2):186-197. doi: 10.1515/cclm-2017-0019. doi: 10.1515/cclm-2017-0019 pmid: 28753534
[30]	Pearl ML, Zhao Q, Yang J, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer[J]. Gynecol Oncol, 2014, 134(3):581-590. doi: 10.1016/j.ygyno.2014.06.013. doi: 10.1016/j.ygyno.2014.06.013
[31]	Pearl ML, Dong H, Tulley S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)[J]. Gynecol Oncol, 2015, 137(2):229-238. doi: 10.1016/j.ygyno.2015.03.002. doi: 10.1016/j.ygyno.2015.03.002
[32]	Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer[J]. Gynecol Oncol, 2017, 145(2):361-365. doi: 10.1016/j.ygyno.2017.02.042. doi: 10.1016/j.ygyno.2017.02.042
[33]	Zeng L, Liang X, Liu Q, et al. The Predictive Value of Circulating Tumor Cells in Ovarian Cancer: A Meta Analysis[J]. Int J Gynecol Cancer, 2017, 27(6):1109-1117. doi: 10.1097/IGC.0000000000000459. doi: 10.1097/IGC.0000000000000459
[34]	Blassl C, Kuhlmann JD, Webers A, et al. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel[J]. Mol Oncol, 2016, 10(7):1030-1042. doi: 10.1016/j.molonc.2016.04.002. doi: 10.1016/j.molonc.2016.04.002
[35]	Mishra DK, Rocha HJ, Miller R, et al. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells[J]. Sci Rep, 2018, 8(1):16569. doi: 10.1038/s41598-018-34983-7. doi: 10.1038/s41598-018-34983-7
[36]	Buderath P, Schwich E, Jensen C, et al. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer[J]. Front Oncol, 2019, 9:1015. doi: 10.3389/fonc.2019.01015. doi: 10.3389/fonc.2019.01015 pmid: 31681568
[37]	Dong H, Tulley S, Zhao Q, et al. The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness[J]. Cancer Med, 2019, 8(8):3864-3874. doi: 10.1002/cam4.2218. doi: 10.1002/cam4.2218
[38]	Geethadevi A, Parashar D, Bishop E, et al. ERBB signaling in CTCs of ovarian cancer and glioblastoma[J]. Genes Cancer, 2017, 8(11/12):746-751. doi: 10.18632/genesandcancer.162. doi: 10.18632/genesandcancer.162